RxDoctor Payments Data

Ijeoma Isiadinso, MD

Cardiovascular Disease · Atlanta, GANPI 1861429771

Payments from drug & device makers

What this record shows

This record is dominated by education: $4,500 of the $4,674 with a category attached, or 96.3%. Pfizer accounts for 96.9% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2024 at $4,607 and has fallen 99.4% since, to $28 in 2025.

$4,674in general payments, 2019–2025

Across 4 payments — averaging $1168.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$5K
  • Amgen$146
$433,730in research payments, 2019–2025

Across 14 payments — averaging $30,981 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$434K

What the payments were for

  • Food & beverage$1744%
  • Education$4,50096%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer2$4,528
Amgen2$146

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,674 in reported general payments places this provider in the 65th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$72,923
Medicare patients
387
Services billed
767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban171$221,983
Repatha SureclickEvolocumab109$119,197
EntrestoSacubitril/Valsartan84$99,642
XareltoRivaroxaban49$69,192
Praluent PenAlirocumab44$41,439
JardianceEmpagliflozin14$23,013
NexlizetBempedoic Acid/Ezetimibe28$19,597
FarxigaDapagliflozin Propanediol14$13,449
Repatha SyringeEvolocumab17$12,601
VascepaIcosapent Ethyl17$7,565
Valsartan95$3,729
Rosuvastatin Calcium322$3,726
Atorvastatin Calcium386$3,361
Metoprolol Succinate265$2,853
Potassium Chloride87$2,803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$4,528$221,983171 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →